Literature DB >> 35368809

Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON.

Patrick H Pun1,2,3, Susan T Crowley4,5.   

Abstract

Entities:  

Keywords:  Gadolinium; chronic kidney disease; nephrogenic systemic fibrosis; safety

Mesh：

Substances：

Year:  2020        PMID： 35368809      PMCID： PMC8785745          DOI： 10.34067/KID.0005572020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  8 in total

1.  Absence of evidence is not evidence of absence.

Authors:  D G Altman; J M Bland
Journal:  BMJ       Date:  1995-08-19

2.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

3.  Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era.

Authors:  Laura K Thomson; Peter C Thomson; David B Kingsmore; Karen Blessing; Conal D Daly; Shawn E Cowper; Giles H Roditi
Journal:  J Magn Reson Imaging       Date:  2014-06-05       Impact factor: 4.813

4.  Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors:  Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

5.  Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

Authors:  Nicola Schieda; Pejman Jabehdar Maralani; Casey Hurrell; Anne K Tsampalieros; Swapnil Hiremath
Journal:  Can Assoc Radiol J       Date:  2019-06-27       Impact factor: 2.248

Review 6.  Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.

Authors:  Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt
Journal:  Kidney Int       Date:  2017-04-20       Impact factor: 10.612

7.  Type of MRI contrast, tissue gadolinium, and fibrosis.

Authors:  Catherine Do; Jeffrey L Barnes; Chunyan Tan; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-06

Review 8.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04
  8 in total
  1 in total

1.  Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY.

Authors:  Ali K Abu-Alfa
Journal:  Kidney360       Date:  2020-12-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.